Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de belimumab administrado por vía subcutánea en adultos con enfermedad pulmonar intersticial (EPI) asociada a enfermedad del tejido conectivo (ETC).

• Protocol code: 221672
• EudraCT code: No aplica
• Research group: Systemic Diseases
• Service: Internal Medicine
• Principal investigator:  Mestre Torres, Jaume
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase III

A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment.

• Protocol code: CLIN-60000-461
• EudraCT code: No aplica
• Research group: Childhood Cancer and Blood Disorders
• Service: Pediatric Oncohematology
• Principal investigator:  Gros Subias, Luís
• Pathology: Tumors
• Phase: Fase II
• Status: Recruiting volunteers

A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)

• Protocol code: CN008-0003
• EudraCT code: No aplica
• Research group: Neurovascular Diseases
• Service: Neurology
• Principal investigator:  Delgado Martínez, Maria Pilar
• Pathology: Malalties del sistema nerviós
• Phase: Fase II

A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy

• Protocol code: I3Y-MC-JPEH
• EudraCT code: No aplica
• Research group: Childhood Cancer and Blood Disorders
• Service: Pediatric Oncohematology
• Principal investigator:  Llort Sales, Anna
• Pathology: Tumors
• Phase: Fase II
• Status: Recruiting volunteers

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema)1.0 mg/1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in participants with type 2diabetes inadequately controlled on metformin, SGLT2 inhibitor or both

• Protocol code: NN9388-7741
• EudraCT code: No aplica
• Research group: Diabetes and Metabolism
• Service: Endocrinology
• Principal investigator:  Ciudin Mihai, Andreea
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase III
• Status: Recruiting volunteers